II. Indications
- Non-Q-Wave Myocardial Infarction
- High risk Unstable Angina
- Percutaneous Coronary Intervention (PCI)
III. Contraindications
- Recent major bleeding
IV. Mechanism
- Fab Antibody fragment
- Inhibits Platelet aggregation via Glycoprotein IIb/IIIa receptors on Platelet plasma membranes
- Inhibits Fibrinogen binding to Platelets
V. Dosing
-
Percutaneous Coronary Intervention (PCI)
- Load: 0.25 mg/kg IV bolus given 10 to 60 minutes before PCI
- Infuse: 0.125 mcg/kg/min up to 10 mcg/min IV for 12 hours
-
Unstable Angina or non-ST-elevation Myocardial Infarction pending PCI within 24 hours
- Dosing as for PCI, with infusion up to 18 to 24 hours, completing at one hour post-PCI
- Coronary Aneursym in Kawasaki Disease
- Off label use for age >2 months old
- Dosing as used in PCI
VI. Safety
- Unknown safety in pregnancy
- Unknown safety in Lactation
- Abciximab is excreted in human milk
VII. Resources
- Abciximab (FDA)
- Stoffer (2022) Abciximab, StatPearls, Treasure Island
Images: Related links to external sites (from Bing)
Related Studies
Definition (NCI) | A Fab fragment of the chimeric monoclonal antibody 7E3 and inhibitor of the glycoprotein (GP) IIb/IIIa receptor, that blocks platelet aggregation. Abciximab binds to the GP IIb/IIIa receptor on the platelet membrane, which inhibits the binding of fibrinogen to the GP IIb/IIIa receptor. This prevents both platelet aggregation and thrombus formation. |
Concepts | Immunologic Factor (T129) , Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121) |
MSH | C085843 |
SnomedCT | 391697004, 386951001, 108974006 |
LNC | LP171382-7 |
English | abciximab, abciximab (medication), MoAb 7E3, Chimeric 7E3 Fab, abciximab [Chemical/Ingredient], Abciximab - chemical (substance), Abciximab - chemical, Abciximab, Abciximab (product), Abciximab (substance), c7E3 Fab, chimeric 7E3 Fab, ABCIXIMAB |
Spanish | abciximab (producto), abciximab (sustancia), abciximab |
Ontology: ReoPro (C0592046)
Concepts | Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) |
MSH | C085843 |
English | ReoPro, Reopro, reopro, Eli Lilly brand of abciximab, Lilly brand of abciximab |